Compare · ICCC vs IDXX
ICCC vs IDXX
Side-by-side comparison of ImmuCell Corporation (ICCC) and IDEXX Laboratories Inc. (IDXX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCC and IDXX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $44.27B, about 504.4x ICCC ($87.8M).
- Over the past year, ICCC is up 46.6% and IDXX is up 8.1% - ICCC leads by 38.5 points.
- IDXX has hit the wire 5 times in the past 4 weeks while ICCC has been quiet.
- IDXX has more recent analyst coverage (23 ratings vs 0 for ICCC).
- Company
- ImmuCell Corporation
- IDEXX Laboratories Inc.
- Price
- $9.86-0.70%
- $561.97-0.07%
- Market cap
- $87.8M
- $44.27B
- 1M return
- +9.92%
- -1.85%
- 1Y return
- +46.62%
- +8.09%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1987
- 1991
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 23
ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest ICCC
- ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by ImmuCell Corporation
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
- Amendment: SEC Form 10-K/A filed by ImmuCell Corporation
- ImmuCell Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
- SEC Form DEF 14A filed by ImmuCell Corporation
- SEC Form 3 filed by new insider Dimarco Anthony
- SEC Form 3 filed by new insider Guillemette Gilles
- SEC Form 4 filed by Turner Kathy V
Latest IDXX
- Executive Vice President Fennell George converted options into 639 shares and covered exercise/tax liability with 284 shares, increasing direct ownership by 4% to 10,433 units (SEC Form 4)
- SEC Form SD filed by IDEXX Laboratories Inc.
- IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
- IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
- The Biology Came First.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Samad Sam
- SEC Form 4 filed by Director Vandebroek Sophie V.
- SEC Form 4 filed by Director Peacock Karen
- SEC Form 4 filed by Director Junius Daniel M